364 filings
Page 5 of 19
6-K
zi3s a5y4diwkk31tn
28 May 20
Current report (foreign)
11:56am
6-K
cca7hvxt fyv9
27 May 20
BioLineRx Announces Publication of Data from Ongoing
7:00am
6-K
nrk6fec
26 May 20
BioLineRx Announces $9.0 Million Registered Direct Offering
8:45am
6-K
pciky8z bqrsy3
26 May 20
Current report (foreign)
8:10am
6-K
xyxo c31b45obn
20 May 20
BioLineRx Reports First Quarter 2020 Financial Results
7:00am
6-K
egsunj
12 Mar 20
BioLineRx Reports Year-End 2019 Financial Results
7:00am
6-K
erpl0pxr82t
5 Mar 20
Current report (foreign)
10:00am
6-K
wcsz748oo39r620
27 Feb 20
BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination with The COMBAT/KEYNOTE-202 Study
7:00am
6-K
l0lyj4
30 Jan 20
Extraordinary General Meeting of Shareholders
7:00am
6-K
grswu s0i7mzg18d4y
22 Jan 20
BioLineRx Completes Recruitment in Triple Combination
7:00am
6-K
kg13zr2n
14 Jan 20
BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of
7:00am
6-K
cg2o0ufjqkhu2vzrr5
13 Dec 19
BioLineRx Announces Updated Phase 2a Data from Triple
7:00am
6-K
bogphmdff bc59abqj
5 Dec 19
BioLineRx Announces Preliminary Phase 2a Data from Triple
7:00am
6-K
lhqd8yew
12 Nov 19
Current report (foreign)
6:21am
6-K
5z3qgvx4xlurf23qpt0e
5 Nov 19
BioLineRx Announces BL-8040 in Combination with KEYTRUDA Shows Clinical Activity in Heavily Pretreated
9:00am
6-K
wtyf2s0
5 Nov 19
BioLineRx Presents Preclinical Data from Triple Combination
8:00am
6-K
t0fcvl 391rzg8g9
25 Sep 19
BioLineRx Announces Dosing of First Patient in Part 2 of
7:00am
6-K
qyh8oqnt sbb0qyg3wjb
3 Sep 19
BioLineRx Successfully Completes Dose-Escalation Part of
7:00am
6-K
90whog
6 Aug 19
BioLineRx Reports Second Quarter 2019 Financial Results
7:11am
6-K
76lsfg5v
2 Jul 19
Current report (foreign)
10:00am